Supernus Pharmaceuticals | SUPN - Net Income


Supernus Pharmaceuticals reported $-58.37M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Abbott USD 928M 149M Jun/2026
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
Aurora Cannabis CAD -71.1M 72.92M Mar/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Canopy Growth CAD -157.11M 94.49M Mar/2026
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Corcept Therapeutics USD 42.14M 73.9M Jun/2026
Eisai JPY 18.24B 21.49B Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Novo Nordisk DKK 20.99B 5.9B Jun/2026
Pacira USD 4.65M 1.74M Jun/2026
Perrigo USD 74.5M 473.1M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Supernus Pharmaceuticals USD -58.37M 56.08M Jun/2026
United Therapeutics USD 333M 58.1M Jun/2026
Xeris Pharmaceuticals USD 2.23M 8.85M Mar/2026